AbbVie 8-K
NegativeEarningsGuidance loweredImpairment / charge
Acquired IPR&D and milestone expenses lower Q3 and FY2026 adjusted EPS guidance.
Filed 2026-10-05 16:07 ET
- 2.02 Results of Operations
- 9.01 Financial Statements and Exhibits
Summary
Q3 2026 expense update with lower Q3 and FY2026 adjusted EPS guidance. AbbVie expects $216M of acquired IPR&D and milestones expense in Q3, reducing adjusted diluted EPS guidance by $0.11 for both the quarter and full year.
Key Figures
- Q3 acquired IPR&D and milestones expense: $216M pre-tax, with an unfavorable $0.11 impact on both GAAP and adjusted diluted EPS. Q3 results are not final and remain subject to closing procedures.
- FY2026 acquired IPR&D and milestones expense in the guidance: $1.251B, including the $216M Q3 expense.
Guidance
| Metric | Period | Guidance | Prior | Direction |
|---|---|---|---|---|
| Adjusted diluted EPS, non-GAAP | Q3 2026 | $3.73-$3.77 | $3.84-$3.88 | Lowered |
| Adjusted diluted EPS, non-GAAP | FY2026 | $13.76-$13.96 | $13.87-$14.07 | Lowered |
FY2026 adjusted diluted EPS guidance excludes acquired IPR&D and milestones expense incurred beyond Q3, which AbbVie says it cannot reliably forecast.
Investor Takeaways
- Watch finalized Q3 results: AbbVie says they may differ from the preliminary estimates.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3